Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20900404 | 1.00 | MEN1 (0.63) | MEN1KMT2AACE2LTA4HBLM | |
| SCHEMBL19069567 | 0.86 | CASP2 (0.59) | MEN1KMT2AACE2LTA4HBLM | |
| SCHEMBL16593142 | 0.85 | MEN1 (0.63) | MEN1KMT2ARECQLSMN1; SMN2CASP2 | |
| SCHEMBL14683533 | 0.84 | GLP1R (0.48) | MEN1KMT2AACE2LTA4HRECQL | |
| SCHEMBL24198474 | 0.84 | GLP1R (0.48) | MEN1KMT2AACE2LTA4HRECQL | |
| SCHEMBL16828262 | 0.84 | LTA4H (0.43) | MEN1KMT2AACE2LTA4HBLM | |
| SCHEMBL19069625 | 0.84 | LTA4H (0.43) | MEN1KMT2AACE2LTA4HBLM | |
| SCHEMBL16472580 | 0.83 | NOD1 (0.50) | MEN1KMT2A | |
| SCHEMBL10088131 | 0.83 | CASP2 (0.56) | ACE2LTA4HCASP2NAAA | |
| SCHEMBL14086890 | 0.82 | KMT2A (0.71) | MEN1KMT2ARECQLSMN1; SMN2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981282-B1 | GROWTH HORMONE COMPOUND FORMULATION | NOVO NORDISK HEALTHCARE AG (CH) | 2020-11-04 | — | — | EP | disclosed |
| EP-2525834-B1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTHCARE AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | GHRHR, SHBG, GHSR | MEN1 335/4885KMT2A 3639/4885ACE2 3232/4885 |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | MEN1 335/4885KMT2A 3466/4885ACE2 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.